Welcome to resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases.

Our lead program selectively inhibits the target of rapamycin complex 1, or TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems as people age, including immune, neurologic, and cardiac function. Our lead product candidate, RTB101, is an oral, selective, and potent TORC1 inhibitor. TORC1 inhibition has been shown to benefit multiple aging-related conditions in preclinical studies, including immunosenescence, which is the decline of a body’s immune system during aging. In two Phase 2 clinical trials that enrolled more than 900 people 65 years and older, RTB101 was observed to improve immune function and reduce the incidence of illness associated with respiratory tract infections, or RTIs. Based on these Phase 2 data, in May 2019, resTORbio initiated our global Phase 3 PROTECTOR program to evaluate the safety and efficacy of RTB101 for reducing the percent of people age 65 and older with clinically symptomatic respiratory illness.